News

Changed practice for single reimbursement for hyaluronic acid

In collaboration with the Reimbursement Committee, the Danish Medicines Agency has decided to change the practice for granting single reimbursement for hyaluronic acid. As of 15 January 2012, we will only grant single reimbursement for hyaluronic acid in exceptional circumstances and not, as we have done thus far, to all patients with osteoarthritis of the knee. In the period up until 15 January 2012, we will introduce a time limit on single reimbursement grants for hyaluronic acid to patients with knee osteoarthritis. In Denmark, hyaluronic acid is available as the two medicines Hyalgan® and Artz®, and they are used for patients with knee osteoarthritis for alleviating pain and improving the function of the knee joint.